BioCryst Pharmaceuticals, Inc. (BCRX) Reports In-Line Q4 EPS
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.99 +0.45%
Revenue Growth %: +13.7%
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +13.7%
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q4 EPS of ($0.29), in-line with the analyst estimate of ($0.29). Revenue for the quarter came in at $5.2 million versus the consensus estimate of $7.34 million.
BioCryst Pharmaceuticals, Inc. sees FY2012 EPS of (n/a). BioCryst Pharmaceuticals, Inc. sees FY2012 revenue of $5 million.
For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.
BioCryst Pharmaceuticals, Inc. sees FY2012 EPS of (n/a). BioCryst Pharmaceuticals, Inc. sees FY2012 revenue of $5 million.
For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Goldman Sachs Double Upgrades Bradsaude SA (SAUD3:BZ) to Buy
- Pfizer reaffirms 2026 guidance after CFO transition news
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
